SavaDx is a blood-based biomarker/diagnostic candidate to detect Alzheimer’s disease.
The underlying science for simufilam supports the development of a diagnostic technology to detect Alzheimer's disease with a simple blood test, called SavaDx.
SavaDx is an early-stage product candidate.
Working with third parties, we are evaluating the use of mass spectrometry to detect FLNA without the use of antibodies.
SavaDx is a lower priority program compared to simufilam.